Oncolytics Biotech revealed their financial results for the second quarter of 2017.

Oncolytics Biotech (TSX:ONC; OTCQX:ONCYF) revealed their financial results for the second quarter of 2017.
As quoted in the press release:

“After selecting metastatic breast cancer as our registration pathway for REOLYSIN^® and announcing statistically significant clinical data in this indication in the second quarter, obtaining Fast Track designation was a key development as we prepare for our End-of-Phase 2 meeting with the FDA,” said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. “We expect to receive guidance from the FDA that will help form the basis of our Phase 3 registration study and expect to announce the outcome of our filings in the fourth quarter. In parallel, we will continue to pursue additional clinical collaborations to study REOLYSIN’s therapeutic potential in combination with other immunotherapies as part of our previously announced clinical development plan.”

Click here to read the full press release.

Source: www.newswire.ca

breast cancer cancer clinical data clinical development plan end of phase 2 meeting fast track designation fda financial results metastatic breast cancer oncolytics biotech Biotech Investing